Recursion Pharmaceuticals Inc. (RXRX) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Recursion Pharmaceuticals...

    NASDAQ: RXRX · Real-Time Price · USD
    4.72
    0.09 (1.94%)
    At close: Sep 26, 2025, 3:59 PM
    4.72
    0.00%
    After-hours: Sep 26, 2025, 07:57 PM EDT

    Recursion Pharmaceuticals Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 58.84M 44.58M 39.68M 10M
    Cost of Revenue
    		 45.24M 42.59M 48.27M 9.1M
    Gross Profit
    		 13.6M 1.99M -8.59M 896K
    Operating Income
    		 -479M -350.06M -245.73M -182.78M
    Interest Income
    		 15.76M 19.12M 6.25M 73K
    Pretax Income
    		 -464.79M -332.13M -239.48M -186.48M
    Net Income
    		 -463.66M -328.07M -239.42M -178.07M
    Selling & General & Admin
    		 178.18M 110.82M 81.6M 57.68M
    Research & Development
    		 314.42M 241.23M 155.7M 135.27M
    Other Expenses
    		 n/a -699K -162K -178K
    Operating Expenses
    		 492.61M 351.35M 237.13M 192.78M
    Interest Expense
    		 1.57M 97K 55K 2.95M
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 537.84M 394.63M 285.41M 192.78M
    Income Tax Expense
    		 -1.13M -4.06M -55K -8.4M
    Shares Outstanding (Basic)
    		 274.21M 207.85M 175.54M 170.27M
    Shares Outstanding (Diluted)
    		 274.21M 207.85M 175.54M 170.27M
    EPS (Basic)
    		 -1.69 -1.58 -1.36 -1.05
    EPS (Diluted)
    		 -1.69 -1.58 -1.36 -1.05
    EBITDA
    		 -426.72M -299.57M -227.66M -174.42M
    EBIT
    		 -463.22M -332.03M -239.42M -183.53M
    Depreciation & Amortization
    		 36.49M 24.4M 19.49M 9.1M

    Add to Watchlist